China, Sept. 18 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of Ivosiditumab Combined with Chemotherapy as Neoadjuvant Therapy in Patients with Resectable SMARCA4deficient NonSmall Cell Lung Cancer: A SingleArm, SingleCenter, Phase II Clinical Study'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600132806
Registration Time: 2026/09/18
Type: Interventional study
Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=342217
Published by HT Digital Content Services with permission ...